What is the most common cause of prostate cancer in men, especially those over 50 with a family history?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Most Common Cause of Prostate Cancer

Prostate cancer is fundamentally a multifactorial disease where genetic factors account for more than 50% of risk, making inherited genetic susceptibility the single most important causative factor, followed by advancing age and race. 1

Primary Causative Factors

Genetic Predisposition (Strongest Factor)

  • Inherited genetic factors are responsible for 40-50% of all prostate cancer cases, representing the largest attributable risk for the disease 2, 1
  • Approximately 9-15% of prostate malignancies are due to clearly identifiable inherited predisposition with specific gene mutations 3, 4
  • Among men with metastatic prostate cancer, 11.8% harbor germline mutations in DNA repair genes, with BRCA2 (5.3%), ATM (1.6%), CHEK2 (1.9%), and BRCA1 (0.9%) being most common 3, 5

Key hereditary syndromes include:

  • BRCA2 mutations confer 2-6 fold increased risk and account for up to 2% of early-onset cases, representing the strongest single-gene hereditary risk factor 3, 6, 7
  • HOXB13 G84E mutation increases risk 3.3-8.6 fold, particularly in men with positive family history and early-onset disease 3
  • Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations) confers 2-5 fold increased risk 5, 7

Family History (Reflects Genetic Susceptibility)

  • Men with one first-degree relative affected have 2.5-fold increased risk; two relatives confer 5-fold risk; three relatives result in 11-fold increased risk 3, 6, 7
  • Genetic analyses demonstrate autosomal dominant inheritance patterns with 88% penetrance in hereditary cases 3, 7
  • Approximately 42% of early-onset prostate cancers (diagnosed before age 55) have a hereditary component 3, 6

Age (Universal Risk Factor)

  • More than 70% of prostate cancer patients are older than 65 years at diagnosis, with median age of 71 years 3, 6
  • More than 90% of prostate cancer deaths occur in men older than 65 years 3, 6
  • A 50-year-old man has a 42% lifetime risk of developing histological prostate cancer, though only 9.5% risk of clinically important disease 3

Race and Ethnicity

  • African American men have 64% higher incidence and 2.3-fold increase in mortality compared to white men (annual incidence: 173.0 vs 97.1 per 100,000) 6, 1
  • African American men present with higher-grade prostatic intraepithelial neoplasia and higher Gleason scores, though stage- and grade-adjusted mortality rates are similar to white men 3
  • Asian males have the lowest incidence globally 8

Important Clinical Caveats

Common pitfall: Clinicians often underestimate the genetic contribution to prostate cancer. Unlike environmental cancers where modifiable risk factors dominate, prostate cancer is primarily driven by inherited susceptibility that cannot be modified through lifestyle changes alone.

Critical distinction: While diet and environmental factors are frequently cited, no dietary or environmental cause has been definitively established as causative for prostate cancer 8. These factors may modify risk in genetically susceptible individuals but are not primary causes.

Actionable implication: The strong genetic basis means that family history assessment and consideration of germline genetic testing should be standard practice, particularly for men with metastatic disease, early-onset disease (age <55), or multiple affected relatives 3, 5.

References

Research

Prostate Cancer: A Review.

JAMA, 2025

Research

Familial prostate cancer.

Seminars in oncology, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.

International journal of molecular sciences, 2021

Guideline

Genetic Risk Factors for Prostate Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Prostate Cancer Risk Factors and Screening

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Acinar Adenocarcinoma of the Prostate: Associated Syndromes and Cancers

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Heterogeneity in genetic susceptibility to prostate cancer.

European journal of internal medicine, 2001

Related Questions

What are the red flags for prostate cancer?
What are the treatment options for a patient with Stage 3 (locally advanced) prostate cancer?
What is the best initial diagnostic step for a 65-year-old male with progressive lower back pain, radiating to the legs, and a history of prostate (prostate cancer) cancer?
What are the recommendations for preventing and managing prostate cancer?
What are the treatment options for prostate cancer?
What booster vaccine is recommended for a 9-year-old child who has already exceeded the age limit for Infanrix hexa (Diphtheria, Tetanus, and Pertussis vaccine)?
Can balancing exercises help a 72-year-old patient with S1 sacral radiculopathy during the acute phase?
What went wrong in the management of a patient with type 2 diabetes, postural orthostatic tachycardia syndrome (POTS), chronic fatigue syndrome, depression, fibromyalgia, irritable bowel syndrome (IBS), migraine, and gastroesophageal reflux disease (GERD), who developed diabetic ketoacidosis (DKA) after being treated for acute appendicitis and kept nil per os (NPO) for an extended period?
What are the risks and recommendations for a patient who took letrozole (an aromatase inhibitor) for 5 days from cycle day 3 to cycle day 7 for fertility treatment?
What is the percentage reduction in urine protein-to-creatinine ratio (UPCR) in patients with IgA nephropathy treated with Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors, such as empagliflozin (Empagliflozin) or canagliflozin (Canagliflozin), over what period of time, and does the presence of Renin-Angiotensin System (RAS) inhibitors affect this outcome?
What is the initial management approach for a patient presenting with pneumonia, considering factors such as age, medical history, and severity of symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.